Slingshot Insights | Oncs Overview

ONCS Overview

Upcoming Projects (ONCS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ONCS)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (ONCS)

Comparing results metastatic melanoma in PD-1 progressing patients. IOVA, IDRA, ONCS, REPL, CMPI all have results at this year's SITC in this 2L PD-1 refractory melanoma population. We ask an expert to compare trial designs and results
Tickers: IOVA, IDRA, ONCS, REPL, CMPI
Execute By: Jan 29, 2021

Upcoming & Overdue Catalysts (ONCS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ONCS)

OncoSec (ONCS) Announces Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
Ticker: ONCS
Occurred on: Nov 09, 2020
OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo
Tickers: ONCS, BMY, MRK
Occurred on: Feb 27, 2017
OncoSec Medical (ONCS) Phase 2 Results Evaluating ImmunoPulse IL-12 and Merck's (MRK) Keytruda in Metastatic Melanoma
Tickers: ONCS, MRK
Occurred on: Feb 23, 2017
OncoSec Medical's (ONCS) Interim Results from Phase 2 Study of ImmunoPulse IL-12 and Merck's (MRK) KEYTRUDA in Unresectable Metastatic Melanoma to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Tickers: ONCS, MRK
Occurred on: Nov 11, 2016

Strategic Initiatives (ONCS)

Don’t see a strategic initiative related to the company you care about? Create your own!